P728 Real world evidence for adalimumab biosimilar, MSB 11022, therapy in inflammatory bowel diseases: Adherence analysis
Notice bibliographique
Résumé
Abstract Background Adherence to medication is crucial for maintaining remission in patients with inflammatory bowel diseases (IBD). Patient-support program (PSP) plays a significant role in education for patients on medication adherence. The objective of this project was to analyze the data collected by Fresenius Kabi PSP (KabiCare) in IBD patients population on their adherence to an adalimumab biosimilar, MSB 11022, in real world practice in Canada. Methods Patients with IBD enrolled in KabiCare and received at least one dose of adalimumab biosimilar, MSB 11022, were follow-up from Feb 2021 to Nov 2022 in Canada. Medication initiation date and stop date, disease types (Crohn’s disease [CD], and ulcerative colitis [UC]) and patient treatment (categorized by naïve to biologic, or switched from other biologics) were recorded in the database. The stop date was the date when KabiCare was informed that medication was discontinued. The patients continuing medication were censored at the maximal follow-up date of analysis, November 9, 2022. Log-rank tests were used for KM (Kaplan-Meier) plot comparison to examine if there were differences in medication adherence between CD and UC, and between naïve group vs. switch group by disease. Results The study sample consisted of 836 patients, 670 (80.0%) of whom had CD, and 266 (31.8%) were in naïve group. KabiCare followed patients for a median time of 291 days (interquartile range: 190-392 days; maximum: 622 days). At 600 days after starting the medicine, the adherence probability was similar for patients with CD and UC (At day-600: 83.4% vs. 82.2%, P=0.26); however, the adherence probability was higher in the switch group compared to naïve group (At day-600: 87.9% vs. 73.5%, P=0.0001). Among patients with CD, the adherence probability was higher with switch group compared to naïve group (At day-600: 88.8% vs. 71.7%, P=0.0001). Among patients with UC, the adherence probably was similar between switch group compared to naïve group (At day-600: 90.5% vs. 76.5%, P=0.11). Conclusion The adherence probability of adalimumab biosimilar, MSB 11022, was over 80% 600-day after initiating therapy, regardless of the type of IBD disease. Compared to patients in naïve group, patients in switch group were more likely to stay on adalimumab therapy. As far as we know, this is the first report of using adalimumab biosimilar, MSB 11022, in real world clinical practice of IBD.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,001 | 0,000 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,001 | 0,000 |
| Bibliométrie | 0,001 | 0,001 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,000 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».